Amgen, Kirin to Develop Cancer Patient Treatment
- Share via
Amgen Inc., the Thousand Oaks biotechnology giant, agreed to jointly develop a treatment for cancer patients undergoing chemotherapy with Japanese beer company Kirin Brewery Co.
Amgen and Kirin, which has a pharmaceutical division, are longtime research and marketing partners for Amgen’s two blockbuster drugs, Epogen and Neupogen.
Under the new agreement, Amgen and Kirin will develop a platelet growth factor, a protein that can potentially treat a common chemotherapy side effect involving a chronic decrease in the number of blood platelets.
Terms of the deal were not disclosed.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
